科创创新药ETF（589720）延续回调，资金逢低买入，连续4日净流入

Group 1 - The core viewpoint of the article highlights a recent pullback in the innovative drug sector, with the Science and Technology Innovation Drug ETF (589720) declining nearly 1%, while funds have seen a net inflow of over 170 million yuan for four consecutive days, indicating a buying opportunity [1] - According to Zhongan International, the recent slight pullback in the pharmaceutical sector presents a bottom-fishing opportunity, driven by a recovery in capital market financing and an increase in overseas trading scale for innovative drugs [1] - The CXO industry is expected to experience performance recovery due to the combination of a recovering domestic demand for innovative drug research and development and the impact of interest rate cuts in the U.S. [1] Group 2 - Looking ahead, the innovative drug sector is primarily driven by expectations surrounding business development (BD), with the re-establishment of BD anticipated to be a key factor in stimulating sector recovery [1] - Data indicates that BD accounts for approximately 40% of the annual total in the fourth quarter, suggesting significant potential for large product expectations [1] - The Science and Technology Innovation Drug ETF focuses on innovative drug companies listed on the Science and Technology Innovation Board, tracking an index of 30 representative high-quality companies, primarily in the high-growth biotech sector [1]